Anti-IL-6 therapies for RA, such as tocilizumab, have been associated with improvements in the atherogenic profile of lipoproteins by modifying HDL in terms of CEC and the expression of SAA, PON1, and PLA2 [106, 107]. Here, IL6 is linked to rheumatoid arthritis.